Catechol–rhodanine derivatives: Specific and promiscuous inhibitors of Escherichia coli deoxyxylulose phosphate reductoisomerase (DXR)

Bioorganic & Medicinal Chemistry
2014.0

Abstract

To develop more effective inhibitors than fosmidomycin, a natural compound which inhibits the deoxyxylulose 5-phosphate reductoisomerase (DXR), the second enzyme of the MEP pathway, we designed molecules possessing on the one hand a catechol that is able to chelate the magnesium dication and on the other hand a group able to occupy the NADPH recognition site. Catechol-rhodanine derivatives (1-6) were synthesized and their potential inhibition was tested on the DXR of Escherichia coli. For the inhibitors 1 and 2, the presence of detergent in the enzymatic assays led to a dramatic decrease of the inhibition suggesting, that these compounds are rather promiscuous inhibitors. The compounds 4 and 5 kept their inhibition capacity in the presence of Triton X100 and could be considered as specific inhibitors of DXR. Compound 4 showed antimicrobial activity against Escherichia coli. The only partial protection of NADPH against the inhibition suggested that the catechol-rhodanine derivatives did not settle in the coenzyme binding site. This paper points out the necessity to include a detergent in the DXR enzymatic assays to avoid false positive when putative hydrophobic inhibitors are tested and especially when the IC50, are in the micromolar range.

Knowledge Graph

Similar Paper

Catechol–rhodanine derivatives: Specific and promiscuous inhibitors of Escherichia coli deoxyxylulose phosphate reductoisomerase (DXR)
Bioorganic & Medicinal Chemistry 2014.0
Non-hydroxamate inhibitors of 1-deoxy-d-xylulose 5-phosphate reductoisomerase (DXR): A critical review and future perspective
European Journal of Medicinal Chemistry 2021.0
Synthesis of tetrazole analogues of phosphonohydroxamic acids: An attempt to improve the inhibitory activity against the DXR
Bioorganic & Medicinal Chemistry Letters 2013.0
Modifications around the hydroxamic acid chelating group of fosmidomycin, an inhibitor of the metalloenzyme 1-deoxyxylulose 5-phosphate reductoisomerase (DXR)
Bioorganic & Medicinal Chemistry Letters 2012.0
Synthesis and Bioactivity of β-Substituted Fosmidomycin Analogues Targeting 1-Deoxy-<scp>d</scp>-xylulose-5-phosphate Reductoisomerase
Journal of Medicinal Chemistry 2015.0
Design, Synthesis, and X-ray Crystallographic Studies of α-Aryl Substituted Fosmidomycin Analogues as Inhibitors of Mycobacterium tuberculosis 1-Deoxy-<scp>d</scp>-xylulose 5-Phosphate Reductoisomerase
Journal of Medicinal Chemistry 2011.0
Coordination Chemistry Based Approach to Lipophilic Inhibitors of 1-Deoxy-<scp>d</scp>-xylulose-5-phosphate Reductoisomerase
Journal of Medicinal Chemistry 2009.0
Synthesis and biological evaluation of phosphate isosters of fosmidomycin and analogs as inhibitors of Escherichia coli and Mycobacterium smegmatis 1-deoxyxylulose 5-phosphate reductoisomerases
Bioorganic &amp; Medicinal Chemistry 2017.0
DXR Inhibition by Potent Mono- and Disubstituted Fosmidomycin Analogues
Journal of Medicinal Chemistry 2013.0
Substrate analogs for the investigation of deoxyxylulose 5-phosphate reductoisomerase inhibition: synthesis and evaluation
Bioorganic &amp; Medicinal Chemistry Letters 2004.0